BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Inflammatory disorder
,
Breast
,
Neocentromeres
,
Phenobarbital
,
rs7903146
,
MYC
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
pF 1
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Neuronal NEU cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in ro…
An active domain SA-2 derived from cystatin-SA, and its antifungal activity.
A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepa…
Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized…
Modulation of Mitochondrial Metabolic Parameters and Antioxidant Enzymes in Healthy and Glaucomatous…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
1% Chloroprocaine(PF) vs. Bupivacaine Spinals
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis…
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ